| A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent (NCT07723118) | Mirati Therapeutics Inc. | 2026-08-05 |
| A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies (NCT07415031) | Mirati Therapeutics Inc. | 2026-05-06 |
| A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) (NCT06875310) | Mirati Therapeutics Inc. | 2025-04-24 |
| Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets (NCT06801418) | Mirati Therapeutics Inc. | 2025-02-04 |
| Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) (NCT05853575) | Mirati Therapeutics Inc. | 2024-02-01 |
| Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) (NCT05840510) | Mirati Therapeutics Inc. | 2023-08-07 |
| A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib (NCT05924152) | Mirati Therapeutics Inc. | 2023-06-29 |
| A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib (NCT05868356) | Mirati Therapeutics Inc. | 2023-06-01 |
| Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation (NCT05737706) | Mirati Therapeutics Inc. | 2023-03-06 |
| A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway (NCT05578092) | Mirati Therapeutics Inc. | 2022-12-02 |
| Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation (NCT05609578) | Mirati Therapeutics Inc. | 2022-11-22 |
| PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor. (NCT05255276) | Mirati Therapeutics Inc. | 2022-02-02 |
| Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) (NCT05178888) | Mirati Therapeutics Inc. | 2022-01-20 |
| Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) (NCT04975256) | Mirati Therapeutics Inc. | 2021-07-28 |
| A Study to Explore the Effect of Acid-reducing Agents (NCT04935112) | Mirati Therapeutics Inc. | 2021-07-07 |
| Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study (NCT04887870) | Mirati Therapeutics Inc. | 2021-06-29 |
| Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) (NCT04793958) | Mirati Therapeutics Inc. | 2021-06-24 |
| PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates (NCT04887194) | Mirati Therapeutics Inc. | 2021-04-08 |
| A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib (NCT04800614) | Mirati Therapeutics Inc. | 2021-03-15 |
| A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib (NCT04772612) | Mirati Therapeutics Inc. | 2021-03-12 |
| Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (NCT04685135) | Mirati Therapeutics Inc. | 2021-02-23 |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 (NCT04613596) | Mirati Therapeutics Inc. | 2020-12-02 |
| Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies (NCT04518046) | Mirati Therapeutics Inc. | 2020-08-11 |
| Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) (NCT04330664) | Mirati Therapeutics Inc. | 2020-04-07 |
| Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NCT03906071) | Mirati Therapeutics Inc. | 2019-07-15 |
| Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 (NCT03785249) | Mirati Therapeutics Inc. | 2019-01-15 |
| Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma (NCT03680521) | Mirati Therapeutics Inc. | 2018-10-10 |
| A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (NCT03606174) | Mirati Therapeutics Inc. | 2018-09-11 |